

## Original Article

\*The members of the Italian Network for Research on Psychoses involved in this study are listed in the Appendix.

**Cite this article:** Antonucci LA *et al* (2023). Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning. *Psychological Medicine* **53**, 5717–5728. <https://doi.org/10.1017/S003329172200294X>

Received: 16 March 2022

Revised: 18 July 2022

Accepted: 31 August 2022

First published online: 11 October 2022

**Key words:**

Italian network for research on psychoses; machine learning; personalized interventions; resilience; schizophrenia

**Author for correspondence:**

Alessandro Bertolino,

E-mail: [alessandro.bertolino@uniba.it](mailto:alessandro.bertolino@uniba.it)

# Clinical and psychological factors associated with resilience in patients with schizophrenia: data from the Italian network for research on psychoses using machine learning

Linda A. Antonucci<sup>1</sup>, Giulio Pergola<sup>1</sup>, Antonio Rampino<sup>1</sup>, Paola Rocca<sup>2</sup>, Alessandro Rossi<sup>3</sup>, Mario Amore<sup>4</sup>, Eugenio Aguglia<sup>5</sup>, Antonello Bellomo<sup>6</sup>, Valeria Bianchini<sup>7</sup>, Claudio Brasso<sup>2</sup>, Paola Bucci<sup>8</sup>, Bernardo Carpiniello<sup>9</sup>, Liliana Dell'Osso<sup>10</sup>, Fabio di Fabio<sup>11</sup>, Massimo di Giannantonio<sup>12</sup>, Andrea Fagiolini<sup>13</sup>, Giulia Maria Giordano<sup>8</sup>, Matteo Marcatilli<sup>14</sup>, Carlo Marchesi<sup>15</sup>, Paolo Meneguzzo<sup>16</sup>, Palmiero Monteleone<sup>17</sup>, Maurizio Pompili<sup>18</sup>, Rodolfo Rossi<sup>3</sup>, Alberto Siracusano<sup>19</sup>, Antonio Vita<sup>20,21</sup>, Patrizia Zeppegno<sup>22</sup>, Silvana Galderisi<sup>8</sup>, Alessandro Bertolino<sup>1</sup>, Mario Maj<sup>8</sup> and Italian Network for Research on Psychoses<sup>1,\*</sup>

<sup>1</sup>Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy;

<sup>2</sup>Department of Neuroscience, Section of Psychiatry, University of Turin, Turin, Italy; <sup>3</sup>Section of Psychiatry,

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; <sup>4</sup>Section of

Psychiatry, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child

Health, University of Genoa, Genoa, Italy; <sup>5</sup>Department of Clinical and Molecular Biomedicine, Psychiatry Unit,

University of Catania, Catania, Italy; <sup>6</sup>Psychiatry Unit, Department of Medical Sciences, University of Foggia,

Foggia, Italy; <sup>7</sup>Unit of Psychiatry, Department of Life, Health and Environmental Sciences, University of L'Aquila,

L'Aquila, Italy; <sup>8</sup>Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy; <sup>9</sup>Section of

Psychiatry, Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy;

<sup>10</sup>Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy;

<sup>11</sup>Department of Neurology and Psychiatry, "La Sapienza" University of Rome, Rome, Italy; <sup>12</sup>Department of

Neuroscience and Imaging, "G. D'Annunzio" University, Chieti, Italy; <sup>13</sup>Department of Molecular Medicine and

Clinical Department of Mental Health, University of Siena, Siena, Italy; <sup>14</sup>Department of Psychiatry, University of

Milan, Milan, Italy; <sup>15</sup>Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy; <sup>16</sup>Psychiatric

Clinic, Department of Neurosciences, University of Padua, Padua, Italy; <sup>17</sup>Department of Medicine, Surgery and

Dentistry "Scuola Medica Salernitana" Section of Neuroscience, University of Salerno, Salerno, Italy; <sup>18</sup>Department

of Neurosciences, Mental Health and Sensory Organs, S. Andrea Hospital, "La Sapienza" University of Rome,

Rome, Italy; <sup>19</sup>Department of Systems Medicine, Psychiatry and Clinical Psychology Unit, "Tor Vergata" University

of Rome, Rome, Italy; <sup>20</sup>Psychiatric Unit, School of Medicine, University of Brescia, Brescia, Italy; <sup>21</sup>Department of

Mental Health, Spedali Civili Hospital, Brescia, Italy and <sup>22</sup>Department of Translational Medicine, Psychiatric Unit,

University of Eastern Piedmont, Novara, Italy

**Abstract**

**Background.** Resilience is defined as the ability to modify thoughts to cope with stressful events. Patients with schizophrenia (SCZ) having higher resilience (HR) levels show less severe symptoms and better real-life functioning. However, the clinical factors contributing to determine resilience levels in patients remain unclear. Thus, based on psychological, historical, clinical and environmental variables, we built a supervised machine learning algorithm to classify patients with HR or lower resilience (LR).

**Methods.** SCZ from the Italian Network for Research on Psychoses ( $N = 598$  in the Discovery sample,  $N = 298$  in the Validation sample) underwent historical, clinical, psychological, environmental and resilience assessments. A Support Vector Machine algorithm (based on 85 variables extracted from the above-mentioned assessments) was built in the Discovery sample, and replicated in the Validation sample, to classify between HR and LR patients, within a nested, Leave-Site-Out Cross-Validation framework. We then investigated whether algorithm decision scores were associated with the cognitive and clinical characteristics of patients.

**Results.** The algorithm classified patients as HR or LR with a Balanced Accuracy of 74.5% ( $p < 0.0001$ ) in the Discovery sample, and 80.2% in the Validation sample. Higher self-esteem, larger social network and use of adaptive coping strategies were the variables most frequently chosen by the algorithm to generate decisions. Correlations between algorithm decision scores, socio-cognitive abilities, and symptom severity were significant ( $p_{FDR} < 0.05$ ).

**Conclusions.** We identified an accurate, meaningful and generalizable clinical-psychological signature associated with resilience in SCZ. This study delivers relevant information regarding psychological and clinical factors that non-pharmacological interventions could target in schizophrenia.

## Introduction

Schizophrenia (SCZ) is a severe psychiatric disorder characterized by heterogeneous clinical manifestations and often associated with real-life functional deficits (Antonucci et al., 2022a; Crespo-Facorro et al., 2021). These functional impairments may have serious consequences on social and occupational adjustment, on patients' ability to perform everyday tasks (Millier et al., 2014), and on indirect costs of the disease, which are three times larger than the direct ones (Mayoral-van Son et al., 2019). The high personal and economic burden associated with SCZ urges researchers to detect new targets for an easier and more effective management, both from pharmacological and non-pharmacological perspectives.

So far, SCZ research has largely focused on a hypothesis-driven approach for the identification of factors associated with an increase in the risk of developing the disorder (Arango et al., 2021; Tandon, Nasrallah, & Keshavan, 2009). This approach has been helpful in many respects, but it does not fully capitalize on the resources available to the individual to deal with the disorder. A paradigm focused on the discovery of factors increasing the likelihood of recovery might be more suitable to foster better clinical management of patients (Fusar-Poli et al., 2021; Kobau et al., 2011). Resilience has been defined as the dynamic ability to adapt, maintain (or change) thoughts and behaviors, and negotiate with the environment in the presence of adverse life events, in order to effectively cope with them. It has been operationalized as *'all the positive resources that may be activated in the context of stress to prevent the development of negative mental health outcomes'* (Morote, Hjemdal, Martinez Uribe, & Corveleyn, 2017). Earlier studies have demonstrated that resilience abilities are plastic over the entire life course (Feder, Fred-Torres, Southwick, & Charney, 2019). Indeed, stressors which the individual can be exposed to across the lifespan, as well as environmental resources, personal attributes, and neurodevelopmental changes, may either facilitate or challenge the individual capacity of adaptation, negotiation, and management of stress. These variations make resilience a dynamic process over time and between individuals (Kalisch et al., 2017; Rutten et al., 2013), rather than a static outcome (e.g. not developing a mental disorder despite the presence of risk factors).

Nevertheless, the importance of resilience as a process for mental health is testified by its association with well-being, quality of life, global functioning, and lifelong health in the general population (Windle, Bennett, & Noyes, 2011). In the absence of disease, higher resilience (HR) abilities seem to be negatively associated with indices of mental illness (i.e. depression, anxiety, and negative emotions), and positively associated with indices of well-being (i.e. perceived quality of life, psychological well-being, and positive emotions) (Shapero et al., 2019; Skrove, Romundstad, & Indredavik, 2013; Smith, 2009; Ungar & Theron, 2020; Windle et al., 2011).

However, resilience abilities seem to be key also in contributing to disease course and levels of symptomatology in severe psychiatric conditions, such as SCZ (Choi et al., 2015; Haefel & Grigorenko, 2007; Hjemdal, Vogel, Solem, Hagen, & Stiles, 2011). Indeed, studies revealed that higher levels of resilience are associated with lower positive and negative symptom severity in chronic SCZ patients (Bozikas & Parlapani, 2016), with a higher chance of full recovery (Torgalsboen, 2012), and with higher service engagement (Tait, Birchwood, & Trower, 2004). Notably, resilience has been associated also with disability and

personal functioning (Torgalsboen, 2012). More specifically, a recent study from the Italian Network for Research on Psychoses highlighted that resilience levels moderated the relationship of real-life functioning with avolition and internalized stigma (Galderisi et al., 2014, 2020). Furthermore, the crucial role of resilience abilities in SCZ onset and course is supported by previous literature showing that individuals at clinical high risk for psychosis, who subsequently converted into frank disease, had lower resilience (LR) levels than those who did not convert (Kim et al., 2013). Notably, cognitive performance, whose deficits are characteristic of SCZ patients at the level of multiple and highly variable neuropsychological domains (Antonucci et al., 2020b),<sup>1</sup> has been previously positively associated with resilience levels in non-clinical populations (Simeon et al., 2007).

This body of evidence suggests that (i) there is variability between patients in residual resilience abilities – associated with the clinical characteristics of the disease –, and (ii) resilience abilities are worth being fostered in clinical populations. However, factors that may potentially foster resilience abilities, especially in the presence of disease conditions, are still poorly investigated. Accurate identification of resilience predictors even in severe mental conditions such as SCZ is crucial as it would potentially allow more accurate targeting of protective factors within non-pharmacological screening and intervention programs. In this respect, resilience abilities have been reported to result from a complex interplay between psychological (e.g. personality traits, self-esteem) (Bajaj, Gupta, & Pande, 2016; Iimura & Taku, 2018), environmental (e.g. stressful life events, characteristics of social systems) (Chen & Kuo, 2020; Seery, Holman, & Silver, 2010; Southwick et al., 2016), and historical/clinical factors (e.g. symptom severity, socio-demographic characteristics) (Bozikas & Parlapani, 2016; Mao & Agyapong, 2021). However, these studies show only limited consistency in identifying resilience-associated characteristics in health and disease. This is mainly due to small samples, absence of validation tests, differences in terms of resilience assessment (Windle et al., 2011), and the use of univariate statistics. A promising way to overcome these shortcomings would be to investigate the discriminative power of a wide variety of variables in determining resilience abilities in SCZ via machine learning. Indeed, machine learning allows quantifying sensitivity, specificity and generalizability of a given set of variables at the single-subject level (Antonucci et al., 2020a, 2020b, 2021), rather than just characterizing group differences.

Therefore, the aims of this study were (i) to investigate predictors of resilience to be potentially fostered even in chronic conditions like SCZ, using supervised machine learning at the single-subject level in a relatively large sample (Dwyer, Falkai, & Koutsouleris, 2018), and (ii) to use algorithmic information to characterize the clinical and psychological profile of patients with resilience abilities. With these aims, we generated a Support Vector Machine algorithm to classify patients with HR from those with LR based on various psychological, historical, clinical, and environmental variables. Furthermore, we investigated the potential clinical relevance of the decision scores derived from the algorithm by testing their correlation with the cognitive and clinical characteristics of patients. We hypothesized that patients with SCZ could be differentiated based on their resilience abilities within a machine learning framework, and that the differentiation performance of the machine learning algorithm would be associated with both cognition and symptom severity.

## Materials and methods

### Sample determination and related statistical analyses

This study was conducted as part of the activities of the Italian Network for Research on Psychoses (Galderisi et al., 2014). Within this consortium, 896 patients with SCZ were recruited at 26 centers. The full list of study inclusion and exclusion criteria is reported in online Supplementary Information S1. Approval of the study protocol was obtained from the Local Ethics Committees of the participating centers. The dataset was randomly split, with a 2:1 ratio, into two samples: Discovery and Validation. Notably, in this random partition procedure, sites were entirely assigned, without any partitioning, either to the Discovery or to the Validation sample (i.e. all patients recruited at a given center were assigned either to the Discovery or to the Validation sample). After this procedure, our Discovery sample was composed of 598 patients recruited at 17 centers, and our Validation sample of 298 patients recruited at 9 different centers.

Each case was defined as having higher or LR, based on the total score obtained at the Resilience Scale for Adults (RSA), a self-reported questionnaire (Bonfiglio, Renati, Hjemdal, & Friborg, 2016) (see online Supplementary Information S2). In the RSA, resilience is operationalized as 'all the positive resources that may be activated in the context of stress to prevent the development of negative mental health outcomes' (Morote et al., 2017). The positive resources to which such operationalization refers to, pertain to the following processes: (1) individual positive dispositional attributes, (2) family support and coherence, and (3) external support systems outside the family (Hjemdal et al., 2011). Therefore, individuals with a higher RSA total score will be more likely to dynamically activate individual and contextual resources at their own advantage to cope with stressful situations.

The median of the total RSA score was calculated in the Discovery sample, and this value was used as a cut-off also in the Validation sample. Then, individuals in both the Discovery and Validation samples having a total RSA value higher than the Discovery median were assigned to the HR group, while those with a score lower than the Discovery median were assigned to the LR group. This was done in order to generate a supervised machine learning algorithm (see section 2.3) aimed at classifying higher *v.* lower observed (i.e. real) resilience levels, instead of algorithm-derived or algorithm-predicted resilience levels. This latter option, indeed, would be more typical of unsupervised – rather than supervised – machine learning strategies (e.g. clustering, partial least squares (Dwyer et al., 2018)).

Sample size divided per recruiting center is reported in Table 1, while demographic and clinical characteristics of HR and LR patients are reported in Table 2. The Chi-square test ( $\chi^2$ ) served to evaluate the potential effects of the center and pharmacological treatment on resilience levels. Two-sample *t* tests were employed to investigate potential demographic and clinical differences between HR and LR individuals within, respectively, Discovery and Validation cohorts. For all tests, the significant level was set at  $\alpha = 0.05$ .

### Assessments

Besides RSA, patients were administered the MATRICS Consensus Cognitive Battery (MCCB) (Keefe et al., 2011) to assess cognitive abilities, and the Positive and Negative Syndrome Scale (PANSS) (Peralta & Cuesta, 1994), to assess symptom severity (see online Supplementary Information S3). Furthermore, patients underwent the following observer-rated and self-rated clinical, historical,

**Table 1.** Sample size of both Discovery (panel A) and Validation (panel B) cohorts, divided across centers

	Whole sample N	LR N	HR N	Center effect $\chi^2, p$
<b>A. Discovery sample</b>				
Total N across centers	598	304	294	34.3, 0.004*
Novara	42	16	26	
Genova	37	24	13	
Parma	37	12	25	
Firenze I	14	5	9	
Pisa I	38	18	20	
L'Aquila	44	23	21	
Chieti I	39	23	16	
Roma S. Lucia	42	25	17	
Roma Tor Vergata	49	28	21	
Napoli Vanvitelli	39	20	19	
Napoli Federico II	16	9	7	
Salerno	40	28	12	
Bari	37	14	23	
Catania	40	18	22	
Cagliari	40	14	26	
Foggia	31	16	15	
Pisa II	13	11	2	
<b>B. Validation sample</b>				
Total N across centers	298	150	148	25.2, 0.001*
Torino	59	28	31	
Milano	39	30	9	
Brescia	39	12	27	
Padova	25	9	16	
Bologna	12	5	7	
Firenze II	7	4	3	
Siena	45	21	24	
Chieti II	40	27	13	
Roma Sapienza	32	14	18	

Abbreviations: LR, lower resilience; HR, higher resilience; N, numerosity,  $\chi^2$ , chi-square test.

environmental and psychological assessments, fully described in online Supplementary Information S3:

- Ad-hoc interview covering historical variables;
- Premorbid Adjustment Scale (PAS) (Shapiro et al., 2009);
- St. Hans Rating Scale (SHRS) (Gerlach et al., 1993), for the evaluation of extrapyramidal side effects;
- Internalized Stigma of Mental Illness (ISMI) (Ritsher, Otilingam, & Grajales, 2003);

**Table 2.** Demographic and clinical characteristics of the Discovery (panel A) and Validation (panel B) samples.

	All subjects (mean ± s.d.)	LR (mean ± s.d.)	HR (mean ± s.d.)	LR v. HR p value
<b>A. Discovery sample</b>				
Gender ratio (F/M)	184/414	89/215	95/199	0.490
Age	39.4 ± 10.7	39.6 ± 11.1	39.3 ± 10.3	0.740
Socio-economic status	26.1 ± 14.8	25.8 ± 15.4	26.4 ± 14.2	0.616
1st Psychopath. Ep. Age	23.07 ± 7.3	22.6 ± 7.4	23.5 ± 7.3	0.123
Illness duration	16.3 ± 10.4	16.9 ± 10.4	15.7 ± 10.5	0.167
1st Psychotic. Ep. Age	23.9 ± 7.2	23.3 ± 7.3	24.5 ± 7.2	0.052
Treatment Typical N	88	54	34	
Treatment Atypical N	411	207	204	from 4 × 2 $\chi^2$ :
Treatment Both N	85	38	47	0.089
Treatment None N	14	5	9	
<b>B. Validation sample</b>				
Gender ratio (F/M)	85/213	38/112	47/101	0.271
Age	41.9 ± 10.3	43.2 ± 10.4	40.7 ± 10.2	0.039*
Socio-economic status	24.5 ± 14.7	23.9 ± 14.8	25.1 ± 14.7	0.443
1st Psychopath. Ep. Age	23.8 ± 6.9	23.4 ± 6.7	24.3 ± 7.2	0.295
Illness duration	18.1 ± 10.9	19.8 ± 11.08	16.4 ± 10.4	0.007*
1st Psychotic. Ep. Age	24.2 ± 6.89	24.6 ± 6.6	24.5 ± 7.2	0.536
Treatment Typical N	40	27	13	
Treatment Atypical N	203	89	114	from 4 × 2 $\chi^2$ :
Treatment Both N	40	24	16	0.011*
Treatment None N	15	10	5	

Abbreviations: F/M, female/male; LR, lower resilience; HR, higher resilience; s.d., standard deviation; N, numerosity; RSA, Resilience Scale for Adults;  $\chi^2$ , chi-square test.

- Brief COPE-Coping Orientation to Problems Experienced (COPE) (Carver, Scheier, & Weintraub, 1989);
- Self-Esteem Rating Scale (SERS) (Lecomte, Corbiere, & Laisne, 2006);
- Recovery Style Questionnaire (RSQ) (Gruber et al., 2018);
- Service Engagement Scale (SES) (Tait, Birchwood, & Trower, 2002);
- Social Network Questionnaire (SNQ) (Ribe, Salamero, Perez-Testor, Valero, & Garcia, 2015);
- The Pervasive Developmental Disorder Behavior Inventory (PDD) (Cohen, Schmidt-Lackner, Romanczyk, & Sudhalter, 2003);
- Calgary Depression Scale for Adults (CDSS) (Schennach-Wolff et al., 2011);
- Specific Level of Functioning Scale (SLOF) (Mucci et al., 2014);
- The UCSD Performance-Based Skill Assessment, version B (UPSA-B) (Mausbach et al., 2008, 2010, 2011).

Total scores and subscale scores from these assessments (total number of variables = 85, online Supplementary Table S1) fed our machine learning algorithm, together with anamnestic information.

### Machine learning pipeline

#### Discovery analyses

The overall machine learning strategy was carried out through the NeuroMiner software, version 1.0 (<https://github.com/neurominer-git?tab=repositories>). We generated an algorithm based on the 85

variables extracted from the afore-mentioned assessments (online Supplementary Table S1) able to classify patients as HR or LR. With this aim, we implemented a mixed inner k-fold/outer leave-site-out (Antonucci et al., 2022b) cross-validation (CV) strategy (see online Supplementary Information, section 4) (Antonucci et al., 2020a, 2020b, 2020c, 2021; Koutsouleris et al., 2018, 2021a, 2021b). This type of nested CV prevents information leaking between individuals used for training and testing the models (Ruschhaupt, Huber, Poustka, & Mansmann, 2004). Indeed, we split the data first into training and test sets on an outer (CV2) cycle, and then we split the resulting training folds again into an inner (CV1), training and test data cycle (Antonucci et al., 2020b; Varma & Simon, 2006). Therefore, nested CV induces a strict separation between training and test data. Specifically, parameter optimization is performed within the inner (CV1) cycle, and generalization error estimation is performed only from the outer (CV2) cycle. This was done in order to identify models that contributed mostly to the classification pattern separating HR and LR (previously identified based on the median RSA total score, see section 2.1) at the inner CV level, in our Discovery sample. To enforce an unbiased estimation of classification generalizability, these models were then applied to the test data at the outer CV level in each Discovery recruiting center separately (e.g. leave-site-out). This choice intended to protect from the center effects on sample size distributions we have found (see Results 3.1 and Table 1), thus guaranteeing geographical generalization to centers unseen (e.g. left-out)

during training. The outer CV level included individuals whose data were not used for training the classification algorithm (Ruschhaupt et al., 2004). We obtained a Support Vector Machine (Noble, 2006) ensemble model based on the 85 variables reported in online Supplementary Table S1. Model performance was measured using sensitivity, specificity, balanced accuracy (BAC), positive predictive value, negative predictive value, and Area under the curve (AUC) based on the class membership probability scores generated through ensemble-based majority voting in the repeated nested CV framework (see online Supplementary Information, section 4). We also assigned statistical significance to the observed classification performance of our model through permutation analysis (see online Supplementary, Information S4). Furthermore, to understand the importance of the input features for generating decisions (i.e. HR or LR patient?), we computed for each feature the probability of being selected for classification purposes within the inner CV loop [i.e. Cross-Validation Ratio (Antonucci et al., 2020a, 2020b, 2021)]. A detailed description of our machine learning pipeline is reported in online Supplementary Information S4.

#### Out-of-sample validation analyses

To investigate whether the machine learning model classifying patients as HR or LR had good generalizability, we performed out-of-sample validation analysis. We applied the SVM ensemble decision model obtained from the Discovery analysis without any in-between re-training steps to our Validation cohort, with totally unseen centers and patients, as already done in previous publications (Antonucci et al., 2020a, 2020b, 2021).

#### Sanity checks

Further, we performed some sanity checks to exclude that the accuracy of our algorithm could have been affected by potential confounds. More specifically, we investigated: (i) whether our machine learning algorithm was associated with the type of pharmacological treatment received by patients (i.e. typical antipsychotics, atypical antipsychotics, both, none), and (ii) whether despite the robust leave-site-out CV implemented, our algorithm could carry any latent recruiting center effect, thus showing poor stability. A full description of the methods of these sanity checks is reported in online Supplementary Information S5.

#### Correlation analysis

To investigate the clinical relevance of our algorithm besides resilience, we investigated the association between single-subject decision scores of our model and, respectively:

- Age, gender and education-corrected standardized MCCB scores (Table 4). For this purpose, we employed both domain-related and overall cognitive and socio-cognitive scores;
- PANSS total, positive, negative [employing only core negative symptoms for subscore computation, as recently recommended by the European Psychiatric Association (Galderisi et al., 2021)], general psychopathology and disorganization scores, according to Wallwork et al. (Wallwork, Fortgang, Hashimoto, Weinberger, & Dickinson, 2012).

A more positive single-subject decision score suggests that a given individual is highly prototypical of the LR class according to the algorithm, while a more negative decision score suggests that a given individual is highly prototypical of the HR class.

**Table 4.** Correlation analysis between Support Vector Machine-based decision scores and cognitive abilities assessed through age, gender and education-corrected Z scores extracted from the MATRICS Consensus Cognitive Battery

MCCB scores	<i>r</i>	<i>p</i> FDR
A. Discovery sample		
Speed of processing	−0.102	0.038*
Attention/Vigilance	−0.062	0.154
Working memory	−0.089	0.054
Verbal learning	−0.076	0.099
Visual learning	−0.068	0.130
Reasoning and problem solving	−0.098	0.038*
Social cognition (MSCEIT + TASIT + FEIT)	−0.052	0.211
Global Composite Score (MCCB + MSCEIT + TASIT + FEIT)	−0.110	0.038*
Global Neurocognitive Score (Global Composite – Social Cognition score)	−0.111	0.038*
MCCCB scores	<i>r</i>	<i>p</i>
B. Validation sample		
Speed of processing	−0.041	0.480
Reasoning and problem solving	−0.080	0.175
Global Composite Score (MCCB + MSCEIT + TASIT + FEIT)	−0.124	0.035*
Global Neurocognitive Score (Global Composite – Social Cognition score)	−0.104	0.079

Abbreviations: MCCB, MATRICS Consensus Cognitive Battery; MSCEIT, Mayer Salovey Caruso Emotional Intelligence Test; TASIT, The Awareness of Social Inference Test; FEIT, Face Emotion Recognition Task.

A more positive decision score suggests that a given individual is highly prototypical of the lower resilience class, while a more negative decision score suggests that a given individual is highly prototypical of the higher resilience class.

We conducted Pearson's *r* correlations first in the Discovery sample. All significant *p* values were <0.05, False Discovery Rate (FDR) corrected (Benjamini & Hockberg, 1995). FDR-corrected correlations found in the Discovery sample were also performed in the Validation sample. For the validation sample, the significance level was set at  $\alpha = 0.05$ .

## Results

### Demographic and clinical differences

The  $\chi^2$  test revealed significant inhomogeneity in the distributions of LR and HR individuals across centers in both cohorts (Discovery  $p = 0.004$ , Validation  $p = 0.001$ ). In the Discovery cohort, HR and LR groups did not differ significantly in terms of demographic and clinical characteristics (all  $p > 0.05$ , Table 2). In the Validation cohort, HR individuals were significantly younger than LR ( $p = 0.039$ ) and had significantly shorter illness duration ( $p = 0.007$ ), probably because of their age. The distribution of pharmacological treatment in use was also significantly different across LR and HR individuals, but only in the Validation sample ( $p = 0.011$ ).

### Machine learning results: discovery sample

The machine learning algorithm based on the scores extracted from the assessments listed in online Supplementary Table S1

correctly classified patients as HR or LR with a cross-validated leave-site-out Balanced Accuracy (BAC) of 74.5% (sensitivity: 76.6%; specificity: 72.4%; AUC: 0.82) and was significant at  $p < 0.001$ . Detailed metrics are reported in Table 3.

We observed that features with the highest Cross-Validation Ratio (i.e. those that were selected the most for classification purposes within the CV framework) included self-esteem total score (assessed with SERS), perceived social affective support (assessed with the SNQ), age at first relapse and use of the positive reframing coping strategy in stressful situations (assessed with COPE) (Fig. 1). Thus, these features were those most contributing to the accuracy of our HR *v.* LR algorithm, such that higher self-esteem, higher perceived social affective support, younger age at first relapse and more frequent use of positive reframing coping strategies were found more often in patients that the algorithm classified as having HR levels.

Results of our sanity checks (section 2.4, fully reported in online Supplementary Information S5) revealed that our algorithm was not significantly associated with any type of pharmacological treatment and showed very good stability despite reshuffling of participants and centers.

### Machine learning results: validation sample

Results from the out-of-sample validation analysis classifying patients as HR or LR and centers from the Validation sample based on the model built in Discovery patients (Results section 3.2) revealed that such model correctly classified patients as HR or LR also when applied to unseen patients and centers (BAC: 80.2%; sensitivity: 80.0%; specificity: 80.32%; AUC: 0.87, Table 3).

### Correlation analysis

To investigate the potential clinical relevance of our algorithm, we tested whether its ability to classify patients with HR or LR correctly is correlated with cognitive and clinical characteristics of patients.

### Cognitive abilities

Pearson's  $r$  analysis revealed significant negative correlations in the Discovery sample between SVM-related decision scores and the speed of processing domain score ( $r = -0.10$ ,  $p\text{FDR} = 0.04$ ), the reasoning/problem-solving domain score ( $r = -0.10$ ,  $p\text{FDR} = 0.04$ ), the global composite score (i.e. cognition + social cognition,  $r = -0.11$ ,  $p\text{FDR} = 0.04$ ), and the composite neurocognitive score (i.e. all MCCB scores minus the social cognition composite score,  $r = -0.11$ ,  $p\text{FDR} = 0.04$ ) of the MCCB (see section 2.5). The correlation between decision scores and MCCB global composite score was replicated in the Validation sample ( $r = -0.12$ ,  $p = 0.04$ ). The full list of correlation results for cognitive abilities is reported in Tables 4A and 4B.

Notably, a more positive decision score suggests that a given individual is highly prototypical of the LR class, while a more negative decision score suggests that a given individual is highly prototypical of the HR class, according to the algorithm. Therefore, this negative correlation suggests that the more a subject is classified within the LR class, the lower is the MCCB global score.


### Symptom severity

Pearson's  $r$  correlation analysis between SVM-related decision scores and PANSS scores (see section 2.5) revealed significant

Table 3. Validated classification performance of the Support Vector Machine algorithm trained within a repeated nested cross-validation framework on the assessments listed in section 1.2

HR <i>v.</i> LR classification	True Neg	True Pos	False Neg	False Pos	Sens	Spec	BAC	Positive predictive value	Negative predictive value	Number needed to diagnose	Area under the curve	DOR	Youden's J statistic
Discovery sample	213	233	71	81	76.6	72.4	74.5	74.2	75.0	2.0	0.82	7.7	0.5
Validation sample	119	120	30	29	80.0	80.4	80.2	80.6	79.8	1.6	0.87	16.6	0.6

Abbreviations: HR, higher resilience; LR, lower resilience; Neg, negative; Pos, positive; Sens, sensitivity; Spec, specificity; BAC, balanced accuracy; DOR, diagnostic odds ratio.



**Fig. 1.** Probability of each feature for being selected in the machine learning Cross-Validation framework. Scores closer to 1 represent a higher probability of being selected for decision by the Support Vector Machine algorithm. Abbreviations: CDSS, Calgary Depression Scale for Adults; SHRS, Saint Hans Rating Scale; SNQ, Social Network Questionnaire; SERS, Self Esteem Rating Scale.

positive correlations in the discovery sample for all scores assessed (i.e. total, disorganization/cognitive, positive, negative, and general psychopathology, all  $p_{FDR} < 0.001$ ). Associations between decision scores and PANSS total, disorganization/cognitive and general psychopathology domain scores were replicated in the Validation sample (all  $p > 0.022$ ). The full list of correlation results for symptom severity is reported in Tables 5A and 5B. These correlations suggest that the more a subject is classified within the LR class, the more severe are the symptoms.

## Discussion

In order to identify which clinical factors are associated with resilience at the single-subject level, we built a supervised machine learning algorithm to classify patients with HR from those with LR based on several psychological, historical, clinical and environmental variables. To do so, we pooled clinical/historical, psychological and environmental data collected at 26 independent Italian centers, into a robust machine learning framework, to derive rules of classification of patients with HR *v.* LR abilities.

Our results support the notion that HR and LR patients can be classified within a machine learning framework based on a parsimonious clinical-psychological signature. This signature proved accurate, stable, generalizable, and clinically relevant, given its association with the clinical and cognitive profile of patients. The good accuracy and sensitivity/specificity balance of the algorithm support our hypothesis regarding the possibility to reliably identify resilience predictors in patients with SCZ. The reliable identification of such predictors has important and intriguing implications for clinical practice, given evidence highlighting the tight connection between resilience and recovery in patients with SCZ), and the existence of associations between resilience levels and, respectively, psychosocial functioning (Galderisi et al., 2020) and life skills (Zizolfi et al., 2019) in patients. Therefore, it is possible to hypothesize that non-pharmacological

**Table 5.** Correlation analysis between Support Vector Machine-based decision scores and symptom severity assessed by PANSS

PANSS scores	<i>r</i>	<i>p</i> <sub>FDR</sub>
A. Discovery sample		
PANSS total	0.272	<0.001*
PANSS disorganization/cognitive	0.151	<0.001*
PANSS positive	0.157	<0.001*
PANSS negative (core)	0.197	<0.001*
PANSS general	0.250	<0.001*
PANSS scores	<i>r</i>	<i>p</i>
B. Validation sample		
PANSS total	0.240	<0.001*
PANSS disorganization/cognitive	0.133	0.022*
PANSS positive	0.099	0.088
PANSS negative (core)	0.035	0.395
PANSS general	0.208	<0.001*

Abbreviations: PANSS, Positive and Negative Syndrome Scale. A more positive decision score suggests that a given individual is highly prototypical of the lower resilience class, while a more negative decision score suggests that a given individual is highly prototypical of the higher resilience class.

interventions may successfully target residual resilience abilities in patients even in chronic conditions. Future studies are warranted to validate this hypothesis.

Our findings also suggest that, within our clinical-psychological signature, variability in resilience is successfully explained by few specific clinical/historical, psychological and environmental factors. More specifically, the factors that played a most prominent role in the decisions of our algorithm (i.e. those most frequently selected

within our nested, leave-site-out CV framework), were self-esteem levels, perceived social affective support, age at first relapse, and the use of positive reframing as a stable coping strategy.

Self-esteem refers to the personal evaluation that anybody can make about her/his worth, which can span between very positive or very negative (Haug *et al.*, 2012). Previous studies have shown that lower self-esteem levels are associated with depressive symptoms in both patients with full-blown psychosis (Karatzias, Gumley, Power, & O'Grady, 2007; Smith *et al.*, 2006) and in individuals at clinical high risk (Bemrose, Akande, & Cullen, 2021; Benavides, Brucato, & Kimhy, 2018). Other studies also found associations between lower self-esteem and psychotic symptoms (Jongeneel, Pot-Kolder, Counotte, van der Gaag, & Veling, 2018; Romm *et al.*, 2011).

Perceived social affective support was the second variable – and the only SNQ dimension – most frequently selected by the algorithm to generate decisions. Studies have shown that the possibility to ask for support within the social network in case of need is positively associated with resilience (Harvey & Boynton, 2021; Satici, Kayis, & Akin, 2013). This is likely due to the fact that sharing feelings and everyday difficulties in the social network would likely reduce the repression of emotions (Magai, Consedine, Fiori, & King, 2009). Interestingly, self-esteem plays a role in this association (Arango *et al.*, 2021; Bajaj *et al.*, 2016). Indeed, in healthy individuals, self-esteem levels mediated the positive association between the possibility to share thoughts and experiences with others, and resilience abilities (Harvey & Boynton, 2021). The fact that another frequently selected variable in our algorithm was the use of positive reframing as a coping strategy in face of difficult situations would be consistent with this view. Indeed, positive reframing reflects coping with stressors through positive re-thinking and subsequent re-interpreting of the stressful situation (Carver *et al.*, 1989). In summary, having a larger social network would allow the individual to feel more comfortable in sharing feelings and thoughts, thus facilitating positive reframing of stressful situations and, consequently, self-esteem and sense of worth (Alparone, Pagliaro, & Rizzo, 2015; Harvey & Boynton, 2021; Pennebaker, Mayne, & Francis, 1997; Satici *et al.*, 2013).

Therefore, the variable selection process of our algorithm proves a good degree of internal coherence and provides intriguing views not only about psychological and environmental processes fostering resilience, but also about relationships between such processes, that could be considered when planning strategies of psychological support for patients. Future studies are warranted to statistically validate, for example via Structural Equation Modeling, the interplay between all the variables selected by the algorithm and resilience, in both healthy and clinical populations.

Notably, when the algorithm generated in the Discovery cohort was applied to unseen patients and new Network centers, it showed remarkable generalizability. Indeed, the same algorithm correctly classified LR and HR patients with high BAC also in the Validation cohort (*i.e.* 80.2%). Besides high generalizability, the algorithm also proved to be stable and not confounded by either pharmacological, or latent recruiting center or sampling confounding effects. Indeed, as our sanity checks showed (Section 2.4, online Supplementary Information S5), newly generated models based on random resampling of both Discovery and Validation cohorts all classified patients as HR or LR with a minimum BAC of 72.9%, and a maximum BAC of 77.5%. As validation and stability of decisions are both of pivotal importance when evaluating reliability and potential translation into clinical

practice of an algorithm (Sanfelici, Dwyer, Antonucci, & Koutsouleris, 2020), we believe that our results argue in favor of the validity of the clinical-psychological signature identified.

These results could inform more effective psychological assessments in patients, by making them less burdening, and more focused on relevant targets. Indeed, SCZ patients are very heterogeneous from the point of view of psychological, clinical, and environmental risk factors which could play a role in SCZ risk pathways. Within such heterogeneity, our accurate and generalizable resilience signature informs clinical practice about the existence of a parsimonious space of resilience predictors which rely mainly on psychological attributes and social network characteristics. Therefore, such psychological and environmental evaluations may be prioritized in clinical assessment sessions to investigate to which extent there is space to promote positive personal abilities – such as resilience – which could support patients in better coping with the experience of the disease. In this framework, our findings may also inform a better definition of individualized psychological interventions aimed at enhancing resilience abilities in patients with SCZ, even in chronic conditions, through the implementation of tailored programs focusing on potentiating self-esteem, coping strategies, and social skills, especially in those who have experienced an earlier disease onset. However, due to the cross-sectional nature of our project, future studies are warranted to test such clinical implications within a longitudinal framework.

Findings from correlation analysis showed that our resilience signature carries relevant information also beyond the resilience framework, thus arguing in favor of its clinical relevance. More specifically, higher decision scores (*i.e.* the more a given individual was considered by the algorithm as being 'lower resilience-like') were associated with worse global level of socio-cognitive abilities in both Discovery and Validation cohorts. Deficits in neurocognitive and social cognition abilities are key characteristics of SCZ and are highly debilitating for patients, given their impact on daily life activities (Antonucci *et al.*, 2020b; Maj *et al.*, 2021). These findings support a recent hypothesis stating that cognition may influence disease course in psychosis via resilience which, in turn, would mediate functional outcomes (Shrivastava, De Sousa, & Lodha, 2019). However, this hypothesis has not been statistically validated yet.

On the other hand, higher decision scores were associated with higher total, general and disorganization/cognitive PANSS scores, thus suggesting that the more the algorithm classified a patient as 'lower resilience', the higher the total, general and disorganization/cognitive symptom severity, as assessed by PANSS. A recent study has highlighted that resilience could act as a mediator also between symptom severity and perceived everyday disability in patients with SCZ (Chen *et al.*, 2019; Millier *et al.*, 2014). Given this finding, the association between our resilience signature and symptom severity would suggest that the variables most frequently selected by our algorithm (*e.g.* self-esteem, positive reframing, richness of the social network) could play a role in such mediation framework. Again, Structural Equation Modeling studies will likely clarify the role, the direction, and the strength of associations within this interplay of variables.

### Limitations

Our study has some limitations. First, the cross-sectional design of this study certainly limits the clinical implications of our findings and does not allow us to elaborate a prognostic hypothesis



regarding the role of the resilience-associated variables we found for early identification and intervention strategies. Therefore, the generalizability of our algorithm is limited to the cross-sectional framework. Furthermore, our sample comprised chronic SCZ patients under stable antipsychotic treatment. We are aware that this issue may represent another potential limitation for the generalizability of our findings. Therefore, replication studies involving participants in earlier stages of the disease, with shorter treatment course (Ventura et al., 2011), could provide further information about the reliability of our results. Another potential limitation is that within the Italian Network for Research on Psychoses, only Italian patients with SCZ have been recruited. Thus, the geographic validation of our algorithm is limited to the national level. Future studies are needed to further understand the generalizability of our findings within and outside Europe. Another important limitation of this study is that resilience was assessed only through the self-report RSA scale, as it was the only resilience measure available within the NIRP consortium. A recent review has pointed out the lack of a gold-standard measure of resilience. Indeed, nineteen measures of resilience have been identified so far, and each is based on a different operationalization of the resilience construct (Windle et al., 2011). Despite RSA seems to be one of the most reliable resilience instruments according to its psychometric profile, high variability between instruments has led to inconsistencies related to the investigation of factors associated with resilience and to accurate prevalence estimates. Furthermore, the RSA and the rest of the reviewed instruments do not consider the adverse events that may have elicited resilience abilities, or the outcome from which resilience should 'protect' from. As recently pointed out (Kalisch et al., 2017), to move to a truly process-oriented definition of resilience, future studies are warranted (i) to assess the construct validity of our results, thus replicating it through the use of other resilience measures, and (ii) to investigate resilience also in light of adverse events and outcomes.

### Conclusions and future directions

We delivered an accurate, generalizable, stable, and meaningful signature classifying patients with SCZ as HR or LR based on a parsimonious set of psychological, clinical and environmental variables. Our signature showed clinical relevance also beyond resilience, given its association with the clinical and cognitive profile of patients. Furthermore, the algorithm provided relevant information, albeit of cross-sectional nature, regarding psychological, clinical and environmental factors modulating residual resilience in patients with SCZ, which could thus be possibly targeted within individualized non-pharmacological interventions.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S003329172200294X>

**Author contributions.** LAA = Writing – original draft, review & editing, Conceptualization, Investigation, Methodology; GP = Writing – review & editing, Methodology; AR1, PR, AR2, MA, EA, AB, VB, CB, PB, BC, LDO, FDF, MDG, AF, GMG, MM, CM, PM1, PM2, MP, RR, AS, AV, PZ = Data Curation, Writing – review & editing; SG, MM = Funding Acquisition, Supervision, Writing – review & editing; AB = Conceptualization, Funding Acquisition, Supervision, Writing – review & editing.

**Financial support.** This paper reflects only the author's views. The funding bodies had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

**Conflict of interest.** Dr Galderisi reported receiving personal fees from Angelini Pharma, Gedeon Richter-Recordati, Innova Pharma-Recordati Group, Janssen Pharmaceutica NV, Lundbeck Italia, Millennium Pharmaceutical, and Sunovion Pharmaceuticals outside the submitted work. Dr Bertolino reported receiving grants and personal fees from Lundbeck and receiving personal fees from Janssen and from Otsuka during the conduct of the study. Dr Pompili reported receiving personal fees from Allergan, Angelini Pharma, FB Health Janssen, Lundbeck, and Otsuka Pharmaceutical. All other authors declare no biomedical financial interests and no potential conflicts of interest.

**Ethical standards.** The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

### References

- Alparone, F. R., Pagliaro, S., & Rizzo, I. (2015). The words to tell their own pain: Linguistic markers of cognitive reappraisal in mediating benefits of expressive writing. *Journal of Social and Clinical Psychology, 34*(6), 495–507. <https://doi.org/10.1521/jscp.2015.34.6.495>.
- Antonucci, L. A., Fazio, L., Pergola, G., Blasi, G., Stolfa, G., Di Palo, P., ... Italian Network for Research on, P. (2022a). Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. *Schizophrenia Research, 240*, 193–203. doi: 10.1016/j.schres.2021.12.029
- Antonucci, L. A., Penzel, N., Pergola, G., Kambeitz-Illankovic, L., Dwyer, D., Kambeitz, J., ... Koutsouleris, N. (2020a). Multivariate classification of schizophrenia and its familial risk based on load-dependent attentional control brain functional connectivity. *Neuropsychopharmacology, 45*(4), 613–621. doi: 10.1038/s41386-019-0532-3
- Antonucci, L. A., Penzel, N., Sanfelici, R., Pigi, A., Kambeitz-Illankovic, L., Dwyer, D., ... Consortium, P. (2022b). Using combined environmental-clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression. *The British Journal of Psychiatry, 1–17*. doi: 10.1192/bjp.2022.16
- Antonucci, L. A., Pergola, G., Pigi, A., Dwyer, D., Kambeitz-Illankovic, L., Penzel, N., ... Bertolino, A. (2020b). A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects. *Biological Psychiatry, 87*(8), 697–707. doi: 10.1016/j.biopsych.2019.11.007
- Antonucci, L. A., Raio, A., Pergola, G., Gelao, B., Papalino, M., Rampino, A., ... Bertolino, A. (2021). Machine learning-based ability to classify psychosis and early stages of disease through parenting and attachment-related variables is associated with social cognition. *BMC Psychology, 9*(1), 47. doi: 10.1186/s40359-021-00552-3
- Antonucci, L. A., Taurino, A., Laera, D., Taurisano, P., Losole, J., Lutricuso, S., ... Puntillo, F. (2020c). An ensemble of psychological and physical health indices discriminates between individuals with chronic pain and healthy controls with high reliability: A machine learning study. *Pain and Therapy, 9*(2), 601–614. doi: 10.1007/s40122-020-00191-3
- Arango, C., Dragioti, E., Solmi, M., Cortese, S., Domschke, K., Murray, R. M., ... Fusar-Poli, P. (2021). Risk and protective factors for mental disorders beyond genetics: An evidence-based atlas. *World Psychiatry, 20*(3), 417–436. doi: 10.1002/wps.20894
- Bajaj, B., Gupta, R., & Pande, N. (2016). Self-esteem mediates the relationship between mindfulness and well-being. *Personality and Individual Differences, 94*, 96–100. <https://doi.org/10.1016/j.paid.2016.01.020>.
- Bemrose, H. V., Akande, I. O., & Cullen, A. E. (2021). Self-esteem in individuals at ultra-high risk for psychosis: A systematic review and meta-analysis. *Early Interventions in Psychiatry, 15*(4), 775–786. doi: 10.1111/eip.13034
- Benavides, C., Brucato, G., & Kimhy, D. (2018). Self-esteem and symptoms in individuals at clinical high risk for psychosis. *The Journal of Nervous and Mental Disease, 206*(6), 433–438. doi: 10.1097/NMD.0000000000000824
- Benjamini, Y., & Hockberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological), 57*(1), 289–300.

- Bonfiglio, N. S., Renati, R., Hjemdal, O., & Friborg, O. (2016). The resilience scale for adults in Italy: A validation study comparing clinical substance abusers with a nonclinical sample. *Psychology of Addictive Behaviors*, 30(4), 509–515. doi: 10.1037/adb0000176
- Bozikas, V., & Parlapani, E. (2016). Resilience in patients with psychotic disorder. *Psychiatrike = Psychiatriki*, 27(1), 13–16. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/27110878>.
- Carver, C. S., Scheier, M. F., & Weintraub, J. K. (1989). Assessing coping strategies: A theoretically based approach. *Journal of Personality and Social Psychology*, 56(2), 267–283. doi: 10.1037//0022-3514.56.2.267
- Chen, H., Xu, J., Mao, Y., Sun, L., Sun, Y., & Zhou, Y. (2019). Positive coping and resilience as mediators between negative symptoms and disability Among patients with schizophrenia. *Frontiers in Psychiatry*, 10, 641. doi: 10.3389/fpsyt.2019.00641
- Chen, Y. L., & Kuo, P. H. (2020). Effects of perceived stress and resilience on suicidal behaviors in early adolescents. *European Child and Adolescent Psychiatry*, 29(6), 861–870. doi: 10.1007/s00078-019-01401-w
- Choi, J. W., Cha, B., Jang, J., Park, C. S., Kim, B. J., Lee, C. S., & Lee, S. J. (2015). Resilience and impulsivity in euthymic patients with bipolar disorder. *Journal of Affective Disorders*, 170, 172–177. doi: 10.1016/j.jad.2014.08.056
- Cohen, I. L., Schmidt-Lackner, S., Romanczyk, R., & Sudhalter, V. (2003). The PDD behavior inventory: A rating scale for assessing response to intervention in children with pervasive developmental disorder. *Journal of Autism and Developmental Disorders*, 33(1), 31–45. doi: 10.1023/a:1022226403878
- Crespo-Facorro, B., Such, P., Nylander, A. G., Madera, J., Resemann, H. K., Worthington, E., ... Newton, R. (2021). The burden of disease in early schizophrenia - a systematic literature review. *Current Medical Research and Opinion*, 37(1), 109–121. doi: 10.1080/03007995.2020.1841618
- Dwyer, D. B., Falkai, P., & Koutsouleris, N. (2018). Machine learning approaches for clinical psychology and psychiatry. *Annual Review of Clinical Psychology*, 14, 91–118. doi: 10.1146/annurev-clinpsy-032816-045037
- Feder, A., Fred-Torres, S., Southwick, S. M., & Charney, D. S. (2019). The biology of human resilience: Opportunities for enhancing resilience across the life span. *Biological Psychiatry*, 86(6), 443–453. doi: 10.1016/j.biopsych.2019.07.012
- Fusar-Poli, P., Correll, C. U., Arango, C., Berk, M., Patel, V., & Ioannidis, J. P. A. (2021). Preventive psychiatry: A blueprint for improving the mental health of young people. *World Psychiatry*, 20(2), 200–221. doi: 10.1002/wps.20869
- Galderisi, S., Mucci, A., Dollfus, S., Nordentoft, M., Falkai, P., Kaiser, S., ... Gaebel, W. (2021). EPA Guidance on assessment of negative symptoms in schizophrenia. *European Psychiatry*, 64(1), e23. doi: 10.1192/j.eurpsy.2021.11
- Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., ... Italian Network For Research on, P. (2014). The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry*, 13(3), 275–287. doi: 10.1002/wps.20167
- Galderisi, S., Rucci, P., Mucci, A., Rossi, A., Rocca, P., Bertolino, A., ... Italian Network for Research on, P. (2020). The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: Stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. *World Psychiatry*, 19(1), 81–91. doi: 10.1002/wps.20700
- Gerlach, J., Korsgaard, S., Clemmesen, P., Lauersen, A. M., Magelund, G., Noring, U., ... Casey, D. E. (1993). The St. Hans rating scale for extrapyramidal syndromes: Reliability and validity. *Acta Psychiatrica Scandinavica*, 87(4), 244–252. doi: 10.1111/j.1600-0447.1993.tb03366.x
- Gruber, M., Rumpold, T., Schrank, B., Sibitz, I., Otzelberger, B., Jahn, R., ... Unger, A. (2018). Recover recovery style from psychosis: A psychometric evaluation of the German version of the Recovery Style Questionnaire (RSQ). *Epidemiology and Psychiatric Sciences*, 29, e4. doi: 10.1017/S2045796018000471
- Haefel, G. J., & Grigorenko, E. L. (2007). Cognitive vulnerability to depression: Exploring risk and resilience. *Child and Adolescent Psychiatric Clinics of North America*, 16(2), 435–448, x. doi: 10.1016/j.chc.2006.11.005
- Harvey, J., & Boynton, K. (2021). Self-disclosure and psychological resilience: The mediating roles of self-esteem and self-compassion. *Interpersona*, 15(1), 90–104. <https://doi.org/10.5964/ijpr.4533>.
- Haug, E., Melle, I., Andreassen, O. A., Raballo, A., Bratlien, U., Oie, M., ... Moller, P. (2012). The association between anomalous self-experience and suicidality in first-episode schizophrenia seems mediated by depression. *Comprehensive Psychiatry*, 53(5), 456–460. doi: 10.1016/j.comppsy.2011.07.005
- Hjemdal, O., Vogel, P. A., Solem, S., Hagen, K., & Stiles, T. C. (2011). The relationship between resilience and levels of anxiety, depression, and obsessive-compulsive symptoms in adolescents. *Clinical Psychology & Psychotherapy*, 18(4), 314–321. doi: 10.1002/cpp.719
- Imura, S., & Taku, K. (2018). Gender differences in relationship between resilience and big five personality traits in Japanese adolescents. *Psychological Reports*, 121(5), 920–931. doi: 10.1177/0033294117741654
- Jongeneel, A., Pot-Kolder, R., Counotte, J., van der Gaag, M., & Veling, W. (2018). Self-esteem moderates affective and psychotic responses to social stress in psychosis: A virtual reality study. *Schizophrenia Research*, 202, 80–85. doi: 10.1016/j.schres.2018.06.042
- Kalisch, R. B. D., Basten, U., Boks, M. P., Bonanno, G. A., Brummelman, E., Chmitorz, A., ... Kleim, B. (2017). The resilience framework as a strategy to combat stress-related disorders. *Nature Human Behaviour*, 1, 784–790. doi: 10.1038/s41562-017-0200-8
- Karatzias, T., Gumley, A., Power, K., & O'Grady, M. (2007). Illness appraisals and self-esteem as correlates of anxiety and affective comorbid disorders in schizophrenia. *Comprehensive Psychiatry*, 48(4), 371–375. doi: 10.1016/j.comppsy.2007.02.005
- Keefe, R. S., Fox, K. H., Harvey, P. D., Cucchiaro, J., Siu, C., & Loebel, A. (2011). Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. *Schizophrenia Research*, 125(2-3), 161–168. doi: 10.1016/j.schres.2010.09.015
- Kim, K. R., Song, Y. Y., Park, J. Y., Lee, E. H., Lee, M., Lee, S. Y., ... Kwon, J. S. (2013). The relationship between psychosocial functioning and resilience and negative symptoms in individuals at ultra-high risk for psychosis. *Australian and New Zealand Journal of Psychiatry*, 47(8), 762–771. doi: 10.1177/0004867413488218
- Kobau, R., Seligman, M. E., Peterson, C., Diener, E., Zack, M. M., Chapman, D., & Thompson, W. (2011). Mental health promotion in public health: Perspectives and strategies from positive psychology. *American Journal of Public Health*, 101(8), e1–e9. doi: 10.2105/AJPH.2010.300083
- Koutsouleris, N., Dwyer, D. B., Degenhardt, F., Maj, C., Urquijo-Castro, M. F., Sanfelici, R., ... Consortium, P. (2021a). Multimodal machine learning workflows for prediction of psychosis in patients with clinical high-risk syndromes and recent-onset depression. *JAMA Psychiatry*, 78(2), 195–209. doi: 10.1001/jamapsychiatry.2020.3604
- Koutsouleris, N., Kambeitz-Ilankovic, L., Ruhrmann, S., Rosen, M., Ruef, A., Dwyer, D. B., ... Consortium, P. (2018). Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: A multimodal, multisite machine learning analysis. *JAMA Psychiatry*, 75(11), 1156–1172. doi: 10.1001/jamapsychiatry.2018.2165
- Koutsouleris, N., Worthington, M., Dwyer, D. B., Kambeitz-Ilankovic, L., Sanfelici, R., Fusar-Poli, P., ... Cannon, T. D. (2021b). Toward generalizable and transdiagnostic tools for psychosis prediction: An independent validation and improvement of the NAPLS-2 risk calculator in the multisite PRONIA cohort. *Biological Psychiatry*, 90(9), 632–642. doi: 10.1016/j.biopsych.2021.06.023
- Lecomte, T., Corbiere, M., & Laisne, F. (2006). Investigating self-esteem in individuals with schizophrenia: Relevance of the self-esteem rating scale-short form. *Psychiatry Research*, 143(1), 99–108. doi: 10.1016/j.psychres.2005.08.019
- Magai, C., Considine, N. S., Fiori, K. L., & King, A. R. (2009). Sharing the good, sharing the bad: The benefits of emotional self-disclosure among middle-aged and older adults. *Journal of Aging and Health*, 21(2), 286–313. doi: 10.1177/0898264308328980
- Maj, M., van Os, J., De Hert, M., Gaebel, W., Galderisi, S., Green, M. F., ... Ventura, J. (2021). The clinical characterization of the patient with primary

- psychosis aimed at personalization of management. *World Psychiatry*, 20(1), 4–33. doi: 10.1002/wps.20809
- Mao, W., & Agyapong, V. I. O. (2021). The role of social determinants in mental health and resilience after disasters: Implications for public health policy and practice. *Frontiers of Public Health*, 9, 658528. doi: 10.3389/fpubh.2021.658528
- Mausbach, B. T., Bowie, C. R., Harvey, P. D., Twamley, E. W., Goldman, S. R., Jeste, D. V., & Patterson, T. L. (2008). Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. *Journal of Psychiatric Research*, 42(4), 320–327. doi: 10.1016/j.jpsychires.2006.12.008
- Mausbach, B. T., Depp, C. A., Bowie, C. R., Harvey, P. D., McGrath, J. A., Thronquist, M. H., ... Patterson, T. L. (2011). Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. *Schizophrenia Research*, 132(2–3), 165–170. doi: 10.1016/j.schres.2011.07.022
- Mausbach, B. T., Harvey, P. D., Pulver, A. E., Depp, C. A., Wolyniec, P. S., Thronquist, M. H., ... Patterson, T. L. (2010). Relationship of the brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. *Bipolar Disorders*, 12(1), 45–55. doi: 10.1111/j.1399-5618.2009.00787.x
- Mayoral-van Son, J., Juncal-Ruiz, M., Ortiz-Garcia de la Foz, V., Cantarero-Prieto, D., Blazquez-Fernandez, C., Paz-Zulueta, M., ... Crespo-Facorro, B. (2019). Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention. *Early Interventions in Psychiatry*, 13(5), 1182–1190. doi: 10.1111/eip.12752
- Millier, A., Schmidt, U., Angermeyer, M. C., Chauhan, D., Murthy, V., Toumi, M., & Cadi-Soussi, N. (2014). Humanistic burden in schizophrenia: A literature review. *Journal of Psychiatric Research*, 54, 85–93. doi: 10.1016/j.jpsychires.2014.03.021
- Morote, R., Hjemdal, O., Martinez Uribe, P., & Corveleyn, J. (2017). Psychometric properties of the Resilience Scale for Adults (RSA) and its relationship with life-stress, anxiety and depression in a Hispanic Latin-American community sample. *PLoS One*, 12(11), e0187954. doi: 10.1371/journal.pone.0187954
- Mucci, A., Rucci, P., Rocca, P., Buccu, P., Gibertoni, D., Merlotti, E., & Italian Network for Research on, P. (2014). The specific level of functioning scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. *Schizophrenia Research*, 159(1), 144–150. doi: 10.1016/j.schres.2014.07.044
- Noble, W. S. (2006). What is a support vector machine? *Nature Biotechnology*, 24(12), 1565–1567. doi: 10.1038/nbt1206-1565
- Pennebaker, J. W., Mayne, T. J., & Francis, M. E. (1997). Linguistic predictors of adaptive bereavement. *Journal of Personality and Social Psychology*, 72(4), 863–871. doi: 10.1037/0022-3514.72.4.863
- Peralta, V., & Cuesta, M. J. (1994). Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. *Psychiatry Research*, 53(1), 31–40. doi: 10.1016/0165-1781(94)90093-0
- Ribe, J. M., Salamero, M., Perez-Testor, C., Valero, A., & Garcia, M. C. (2015). Spanish version of the social network questionnaire in schizophrenia patients' caregivers. *Schizophrenia Research*, 164(1–3), 273–274. doi: 10.1016/j.schres.2015.03.008
- Ritsher, J. B., Otilingam, P. G., & Grajales, M. (2003). Internalized stigma of mental illness: Psychometric properties of a new measure. *Psychiatry Research*, 121(1), 31–49. doi: 10.1016/j.psychres.2003.08.008
- Romm, K. L., Rossberg, J. I., Hansen, C. F., Haug, E., Andreassen, O. A., & Melle, I. (2011). Self-esteem is associated with premorbid adjustment and positive psychotic symptoms in early psychosis. *BMC Psychiatry*, 11, 136. doi: 10.1186/1471-244X-11-136
- Ruschhaupt, M., Huber, W., Poustka, A., & Mansmann, U. (2004). A compendium to ensure computational reproducibility in high-dimensional classification tasks. *Statistical Applications in Genetics and Molecular Biology*, 3, Article37, Epub 2004 Dec 19, 1–24. doi:10.2202/1544-6115.1078
- Rutten, B. P., Hammels, C., Geschwind, N., Menne-Lothmann, C., Pishva, E., Schruers, K., ... Wichers, M. (2013). Resilience in mental health: Linking psychological and neurobiological perspectives. *Acta Psychiatrica Scandinavica*, 128(1), 3–20. doi: 10.1111/acps.12095
- Sanfelici, R., Dwyer, D. B., Antonucci, L. A., & Koutsouleris, N. (2020). Individualized diagnostic and prognostic models for patients with psychosis risk syndromes: A meta-analytic view on the state of the art. *Biological Psychiatry*, 88(4), 349–360. doi: 10.1016/j.biopsych.2020.02.009
- Satici, S. A., Kayis, A. R., & Akin, A. (2013). Predictive role of authenticity on psychological vulnerability in Turkish university students. *Psychological Reports*, 112(2), 519–528. doi: 10.2466/02.07.PR0.112.2.519-528
- Schennach-Wolff, R., Obermeier, M., Seemuller, F., Jager, M., Messer, T., Laux, G., ... Riedel, M. (2011). Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. *Acta Psychiatrica Scandinavica*, 123(3), 228–238. doi: 10.1111/j.1600-0447.2010.01608.x
- Seery, M. D., Holman, E. A., & Silver, R. C. (2010). Whatever does not kill us: Cumulative lifetime adversity, vulnerability, and resilience. *Journal of Personality and Social Psychology*, 99(6), 1025–1041. doi: 10.1037/a0021344
- Shapero, B. G., Farabaugh, A., Terechina, O., DeCross, S., Cheung, J. C., Fava, M., & Holt, D. J. (2019). Understanding the effects of emotional reactivity on depression and suicidal thoughts and behaviors: Moderating effects of childhood adversity and resilience. *Journal of Affective Disorders*, 245, 419–427. doi: 10.1016/j.jad.2018.11.033
- Shapiro, D. I., Marengo, S., Spoor, E. H., Egan, M. F., Weinberger, D. R., & Gold, J. M. (2009). The premorbid adjustment scale as a measure of developmental compromise in patients with schizophrenia and their healthy siblings. *Schizophrenia Research*, 112(1–3), 136–142. doi: 10.1016/j.schres.2009.04.007
- Shrivastava, A., De Sousa, A., & Lodha, P. (2019). Resilience as a psychopathological construct for psychiatric disorders. *Advances in Experimental Medicine and Biology*, 1192, 479–489. doi: 10.1007/978-981-32-9721-0\_23
- Simeon, D., Yehuda, R., Cunill, R., Knutelska, M., Putnam, F. W., & Smith, L. M. (2007). Factors associated with resilience in healthy adults. *Psychoneuroendocrinology*, 32(8–10), 1149–1152. doi: 10.1016/j.psyneuen.2007.08.005
- Skrove, M., Romundstad, P., & Indredavik, M. S. (2013). Resilience, lifestyle and symptoms of anxiety and depression in adolescence: The Young-HUNT study. *Social Psychiatry and Psychiatric Epidemiology*, 48(3), 407–416. doi: 10.1007/s00127-012-0561-2
- Smith, B., Fowler, D. G., Freeman, D., Bebbington, P., Bashforth, H., Garety, P., ... Kuipers, E. (2006). Emotion and psychosis: Links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. *Schizophrenia Research*, 86(1–3), 181–188. doi: 10.1016/j.schres.2006.06.018
- Smith, P. R. (2009). Resilience: Resistance factor for depressive symptom. *Journal of Psychiatric and Mental Health Nursing*, 16(9), 829–837. doi: 10.1111/j.1365-2850.2009.01463.x
- Southwick, S. M., Sippel, L., Krystal, J., Charney, D., Mayes, L., & Pietrzak, R. (2016). Why are some individuals more resilient than others: The role of social support. *World Psychiatry*, 15(1), 77–79. doi: 10.1002/wps.20282
- Tait, L., Birchwood, M., & Trower, P. (2002). A new scale (SES) to measure engagement with community mental health services. *Journal of Mental Health*, 11(2), 191–198. doi: 10.1080/09638230020023570-2
- Tait, L., Birchwood, M., & Trower, P. (2004). Adapting to the challenge of psychosis: Personal resilience and the use of sealing-over (avoidant) coping strategies. *The British Journal of Psychiatry*, 185, 410–415. doi: 10.1192/bjp.185.5.410
- Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009). Schizophrenia, “just the facts” 4. Clinical features and conceptualization. *Schizophrenia Research*, 110(1–3), 1–23. doi: 10.1016/j.schres.2009.03.005
- Torgalsboen, A. K. (2012). Sustaining full recovery in schizophrenia after 15 years: Does resilience matter? *Clinical Schizophrenia & Related Psychoses*, 5(4), 193–200. doi: 10.3371/CSRP.5.4.3
- Ungar, M., & Theron, L. (2020). Resilience and mental health: How multisystemic processes contribute to positive outcomes. *The Lancet. Psychiatry*, 7(5), 441–448. doi: 10.1016/S2215-0366(19)30434-1
- Varma, S., & Simon, R. (2006). Bias in error estimation when using cross-validation for model selection. *BMC Bioinformatics*, 7, 91. doi: 10.1186/1471-2105-7-91
- Ventura, J., Subotnik, K. L., Guzik, L. H., Helleman, G. S., Gitlin, M. J., Wood, R. C., & Nuechterlein, K. H. (2011). Remission and recovery during the first outpatient year of the early course of schizophrenia. *Schizophrenia Research*, 132(1), 18–23. doi: 10.1016/j.schres.2011.06.025
- Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). Searching for a consensus five-factor model of the positive and

- negative syndrome scale for schizophrenia. *Schizophrenia Research*, 137 (1-3), 246–250. doi: 10.1016/j.schres.2012.01.031
- Windle, G., Bennett, K. M., & Noyes, J. (2011). A methodological review of resilience measurement scales. *Health and Quality of Life Outcomes*, 9, 8. doi: 10.1186/1477-7525-9-8
- Zizolfi, D., Poloni, N., Caselli, I., Ielmini, M., Lucca, G., Diurni, M., ... Callegari, C. (2019). Resilience and recovery style: A retrospective study on associations among personal resources, symptoms, neurocognition, quality of life and psychosocial functioning in psychotic patients. *Psychology Research and Behavior Management*, 12, 385–395. doi: 10.2147/PRBM.S205424
- Brando, Luigi Giuliani, Pasquale Pezzella (University of Campania 'Luigi Vanvitelli', Naples); Carmen Concerto, Laura Fusar Poli, Alessandro Rodolico (University of Catania); Giovanni Martinotti, Mauro Pettorrosso, Stefano Sensi (University of Chieti); Mario Altamura, Livia Ficarella, Simona Biancofiore (University of Foggia); Pietro Calcagno, Valeria Placenti, Gianluca Serafini (University of Genoa); Rita Roncone, Laura Giusti, Silvia Mammarella, Ramona Di Stefano, Arianna Di Berardo, Luca Bonanni (University of L'Aquila); Carla Gramaglia, Eleonora Gambaro, Eleonora Gattoni (University of Eastern Piedmont, Novara); Angela Favaro, Elena Tenconi, Enrico Collantoni (University of Padua); Matteo Tonna, Paolo Ossola, Maria Lidia Gerra (University of Parma); Claudia Carmassi, Barbara Carpita, Ivan Mirko Cremone (University of Pisa); Giammarco Cascino, Giulio Corrivetti, Gianfranco Del Buono (Department of Mental Health, Salerno); Tommaso Accinni, Marianna Frascarelli, Antonino Buzzanca, Anna Comparelli, Roberto Brugnoli, Valentina Corigliano ('La Sapienza' University of Rome); Simone Bolognesi, Alessandro Cuomo, Arianna Goracci (University of Siena); Giorgio Di Lorenzo, Cinzia Niolu, Michele Ribolsi ('Tor Vergata' University of Rome); Silvio Bellino, Paola Bozzatello, Cristiana Montemagni (University of Turin).

## Appendix

Members of the Italian Network for Research on Psychoses involved in this study include: Ileana Andriola, Giuseppe Blasi, Laura De Mastro, Enrico D'Ambrosio, Francesco Massari, Alessandra Raio, Marianna Russo, Pierluigi Selvaggi, Angelantonio Tavella (University of Bari); Stefano Barlati, Giacomo Deste, Jacopo Lisoni (University of Brescia); Federica Pinna, Pasquale Paribello, Luca Marras (University of Cagliari); Giuseppe Piegari, Francesco